Although somatic cell reprogramming to generate inducible pluripotent stem cells (iPSCs) is associated with profound epigenetic changes, the roles and mechanisms of epigenetic factors in this process remain poorly understood. Here, we identify Jmjd3 as a potent negative regulator of reprogramming. Jmjd3-deficient MEFs produced significantly more iPSC colonies than did wild-type cells, whereas ectopic expression of Jmjd3 markedly inhibited reprogramming. We show that the inhibitory effects of Jmjd3 are produced through both histone demethylase-dependent and -independent pathways. The latter pathway involves Jmjd3 targeting of PHF20 for ubiquitination and degradation via recruitment of an E3 ligase, Trim26. Importantly, PHF20-deficient MEFs could not be converted to fully reprogrammed iPSCs, even with knockdown of Jmjd3, Ink4a, or p21, indicating that PHF20 is required for reprogramming. Our findings demonstrate, to the best of our knowledge, a previously unrecognized role of Jmjd3 in cellular reprogramming and provide molecular insight into the mechanisms by which the Jmjd3-PHF20 axis controls this process.
INTRODUCTION
Both human and mouse somatic cells can be reprogrammed to a pluripotent embryonic stem cell (ESC)-like state, giving rise to induced pluripotent stem cells (iPSCs) by the use of four key transcription factors: Oct4, Sox2, Klf4, and c-Myc (Takahashi et al., 2007b; Takahashi and Yamanaka, 2006; Yu et al., 2007) . Because of their similarity to ESCs in terms of gene expression profile, epigenetics/genetic marks, and their ability to self-renew and differentiate into many different cell types, iPSCs hold great promise for human disease modeling, drug screening, and perhaps therapeutic applications (Robinton and Daley, 2012; Stadtfeld and Hochedlinger, 2010) . Although somatic cell reprogramming can be achieved by several strategies (Hanna et al., 2009; Robinton and Daley, 2012; Stadtfeld and Hochedlinger, 2010) , its efficiency and the kinetics of iPSC generation are still suboptimal, suggesting the existence of substantial genetic and epigenetic barriers during reprogramming.
Many factors, including cell proliferation and cycling, mesenchymal-to-epithelial transitions, epigenetic regulation of histone modification, and DNA methylation, influence reprogramming efficiency (Plath and Lowry, 2011; Stadtfeld and Hochedlinger, 2010) . Transiently enforced expression of reprogramming factors leads to separable events, beginning with mesenchymal-to-epithelial transitions associated with loss of the somatic marker THY1, followed by the activation of embryonic markers such as alkaline phosphatase (AP) and stage-specific embryonic antigen 1 (SSEA1) (Li et al., 2010; Plath and Lowry, 2011) . Induction and maintenance of endogenous pluripotency genes such as Nanog and Oct4 require further epigenetic reprogramming changes at the DNA methylation and histone modification levels (Stadtfeld and Hochedlinger, 2010) . Failure to achieve these epigenetic changes in a timely manner can lead to partially reprogrammed iPSCs.
Global analysis of euchromatin dynamics during the reprogramming process has revealed orchestrated epigenetic changes at the histone modification level (Gaspar-Maia et al., 2011; Hemberger et al., 2009; Koche et al., 2011) . Both ESCs and iPSCs contain ''bivalent domains,'' where nucleosomes are marked with trimethylation at histone3-lysine27 (H3K27me3) and histone3-lysine4 (H3K4me3) (Gaspar-Maia et al., 2011) . Whereas the Polycomb group (PcG) complex mediates H3K27 methylation and inhibits gene expression (Margueron and Reinberg, 2011) , Jmjd3 and Utx mediate H3K27 demethylation (Agger et al., 2007; Lan et al., 2007) . Thus, given the importance of epigenetic factors in defining cell lineages, it is reasonable to suggest that some of these factors are required for efficient somatic reprogramming, whereas others may function as negative regulators. Removal of such roadblocks to successful reprogramming will require increased insight into the molecular mechanisms by which epigenetic factors control cell lineage and, hence, the dynamic process of reprogramming. Here, we report identification of Jmjd3 as a potent negative regulator of somatic cell reprogramming in screening studies of a panel of histone-modifying proteins. Knockdown or ablation of Jmjd3 enhanced the efficiency and kinetics of reprogramming, apparently by dual mechanisms: (1) Jmjd3 partially inhibits iPSC reprogramming by promoting cell senescence through upregulation of p21 and Ink4a, and (2) Jmjd3 targets PHF20 (plant homeodomain finger protein 20) for ubiquitination and proteasomal degradation via the E3 ubiquitin ligase Trim26 in a demethylase activity-independent manner. Knockdown or ablation of PHF20 blocks the reactivation of endogenous Oct4 expression, thus leading to partially reprogrammed cells. Our results implicate the Jmjd3-PHF20 axis as a key pathway in somatic cell reprogramming and provide insights into the molecular mechanisms used by Jmjd3 to impede efficient reprogramming.
RESULTS

Identification of Jmjd3 as an Inhibitor of Reprogramming
To establish a simpler and inducible 4F-based method to generate iPSCs, we created transgenic mice expressing tetracycline (Tet)-O-inducible Oct4, Sox2, Klf4, and Myc transgenic mice carrying rtTA-M2 reverse tetracycline transactivator ( Figure 1A ). Mouse embryonic fibroblasts (MEFs) were generated from intercrossing transgenic mice (Figure S1A available online). As shown in Figure 1B, Oct4, Sox2, Klf4 , and Myc proteins were readily detected by immunoblot analysis after treatment with Dox for 24 hr. These 4F-expressing MEFs (Tet-O-4F MEFs) could be efficiently reprogrammed to generate iPSCs in the presence of Dox ( Figure 1C ). Withdrawal of Dox before or at day 8 markedly reduced AP + colony formation, but withdrawal at day 10 or later showed little or no effect on AP + colony number using three different types of MEFs (wild-type [WT], Tet-O-4F, and Oct4-GFP) ( Figures S1B-S1D ). The fully reprogrammed iPSCs stained positively for AP, SSEA-1, and Nanog ( Figures 1D-1G ), suggesting that Tet-O-4F MEF-based reprogramming would provide a reliable system to screen for epigenetic factors that either enhance or reduce the efficiency of reprogramming.
We predicted that epigenetic factors play critical roles in reactivating the expression of stem-cell-enriched genes, while shutting down the expression of cell-lineage-specific differentiation genes, thus greatly increasing the efficiency of 4F-mediated reprogramming. To test this notion, we selected a panel of small hairpin RNAs (shRNAs) with high knockdown efficiency (>70%) against a subset of genes encoding histone methyltransferases or demethylases based on PCR or western blot analysis (Figures S1E and S1F and Tables S1 and S2) . After three rounds of screening, we found that knockdown of the H3K27 methyltransferase Ezh2 and many histone demethylase genes, including Fbxl10, Jarid1b, Jarid1d, Jarid2, Jmjd1a, Jmjd2c, and Utx, markedly decreased reprogramming efficiency ( Figure 1H ), which is consistent with recent findings for Utx and Fbxl10 (Mansour et al., 2012; Wang et al., 2011) . By contrast, knockdown of Jmjd3 markedly increased the efficiency of 4F-mediated reprogramming, whereas its ectopic expression resulted in decreased reprogramming efficiency ( Figure 1I ), suggesting that Jmjd3 functions as a barrier to somatic reprogramming. This unique feature of Jmjd3 led to its selection for further study.
Jmjd3 Ablation Enhances the Efficiency and Kinetics of Reprogramming
To further define the role of Jmjd3 in reprogramming, we generated Jmjd3 knockout (KO) mice by targeted deletion of exons 15-21 using a Cre-LoxP system (Figure 2A ). Mice with global deletion of Jmjd3 died shortly after birth due to lung dysfunction (Q.L., H.Y.W., I. Chepelev, G. Wei, K. Zhao, and R.-F. Wang, unpublished data). Expression of Jmjd3 was abrogated in Jmjd3-deficient MEFs (Figure 2A ). Consistent with results obtained by Jmjd3 knockdown, 4F-reprogramming of Jmjd3-deficienct MEFs produced significantly more iPSC colonies than did WT MEFs ( Figure 2B ). Robust reprogramming was also achieved with Jmjd3-deficient 3F-transduced MEFs (Oct4, Sox2, and Klf4), compared with WT MEFs ( Figure 2B ). By contrast, Ezh2-deficient MEFs, which were generated by treating Ezh 2 flox/flox :Cre-ESR MEFs with tamoxifen, strikingly inhibited the efficiency of 4F-mediated reprogramming of MEFs ( Figure 2C ), further confirming that Ezh2 is necessary for reprogramming. More importantly, we found that AP + iPSC colonies appeared much earlier in Jmjd3-deficient MEFs than in WT MEFs ( Figure 2D ). The iPSCs generated from Jmjd3-deficient MEFs showed characteristic ESC morphology and expressed markers such as AP, SSEA-1, and Nanog ( Figures 2E-2G ). They also formed teratomas comprising all three embryonic germ layers ( Figures 2H and 2I ) and contributed to chimeras after injection into BALB/C host blastocysts ( Figure 2J ). Taken together, these results suggest that loss of Jmjd3 markedly enhances the efficiency and kinetics of iPSC reprogramming.
Jmjd3 Inhibits Reprogramming by Modulating
Expression of the Ink4a/Arf Locus We next asked how Jmjd3 ablation enhances reprogramming. Jmjd3 is thought to increase the expression of Ink4a/Arf in MEFs by modifying H3K27 methylation in the promoter region of the Ink4a/Arf locus (Agger et al., 2009; Barradas et al., 2009 ). Knockdown or deletion of Ink4a/Arf and p21 reduces cell senescence and markedly increases the efficiency of reprogramming (Hong et al., 2009; Kawamura et al., 2009; Li et al., 2009; Marió n et al., 2009; Utikal et al., 2009 To determine the relative contribution of downregulation of Ink4a/Arf and p21 to increased efficiency of reprogramming in Jmjd3-deficient MEFs, we knocked down the expression of these genes with specific shRNAs ( Figure S2B ). Although knockdown of Jmjd3, Ink4a/Arf, or p21 alone by shRNAs increased reprogramming efficiency, compared to that in MEFs transduced with a control shRNA, the efficiency nearly doubled with simultaneous knockdown of Jmjd3 and Ink4a/Arf or p21 (Figure 3D ), suggesting that Jmjd3 might have additional effects on reprogramming. To test this possibility, we generated Jmjd3-N (containing the N-terminal 450 aa), Jmjd3-DJmjC (containing a deletion in the catalytic Jumonji domain), and Jmjd3-H1390A (containing a point mutation in the catalytic domain) constructs, all of which lack the H3K27me3 demethylase activity toward H3K27 trimethylation ( Figure S2C ). To determine whether Jmjd3-mediated inhibition of reprogramming depends upon expression of Ink4a/Arf and p21, we showed that ectopic expression of fulllength Jmjd3, but not Jmjd3-N, Jmjd3-DJmjC, or Jmjd3-H1390A, in Jmjd3-deficient MEFs restored the expression of Ink4a/Arf ( Figure 3E ) and markedly inhibited reprogramming (Figure 3F) . Surprisingly, two Jmjd3 mutants (Jmjd3-DJmjC and Jmjd3-H1390A) that lacked H3K27 demethylase activity and failed to upregulate Ink4a/Arf expression were still capable of inhibiting reprogramming in Jmjd3-deficient MEFs (Figure 3F ), suggesting that Jmjd3 can modulate reprogramming through a previously unknown, demethylase activity-independent pathway.
PHF20 Is a Key Target of the Jmjd3 Protein
To search for the targets of Jmjd3, we performed a comparative analysis of microRNA (miRNA) and messenger RNA (mRNA) gene expression between WT and Jmjd3-deficient MEFs but failed to identify any gene that could be responsible for the increased reprogramming efficiency in Jmjd3-deficient MEF cells (data not shown). Hence, we turned our attention to the expression levels of epigenetic factors because they are critical in reprogramming somatic cells to an ESC-like state (Plath and Lowry, 2011; Stadtfeld and Hochedlinger, 2010) . By comparing the expression of 59 genes that encode histone modification proteins, we identified 18 genes that were markedly upregulated at the RNA level in iPSCs/ESCs versus MEFs and 11 genes that were upregulated between iPSCs/ESCs versus human fibroblasts ( Figure S2D and S2E). Among them, seven genes were highly expressed in both mouse and human ( Figure S2F ). Of these, only PHF20 (also called GLEA2) showed a marked increase of expression in Jmjd3-deficient MEFs, iPSCs, and ESCs versus WT MEFs ( Figure 3G ). However, no appreciable differences in PHF20 mRNA and H3K27 trimethylation were observed between WT and Jmjd3-deficient MEFs (Figures S3A and S3B). PHF20 was strongly expressed in testis, ovary, and ES cells but was weakly expressed in other tissues (Figures S3C and S3D) . Interestingly, PHF20 expression gradually increased in WT MEFs during reprogramming, which was accelerated in Jmjd3-deficient MEFs ( Figure 3H ). These results suggest that the PHF20 protein is an important target of Jmjd3 and thus may play a role in ESCs and iPSCs.
Requirement for PHF20 in the Maintenance and Reprogramming of ESCs and iPSCs
Because the PHF20 protein is abundantly expressed in both ESCs and iPSCs, we next sought to determine its importance in the maintenance of these cell types. After knocking down PHF20 in ESCs with specific shRNAs containing a green fluorescent protein (GFP) cassette ( Figure S4A ), ESCs underwent differentiation, whereas ESCs transduced with control shRNA remained undifferentiated ( Figure 4A ). Furthermore, RT-PCR and western blot analyses revealed that PHF20 expression in ESCs, like that of Oct4 and Nanog, was markedly reduced after withdrawal of leukemia-inhibiting factor (LIF) and addition of retinoic acid (RA) in the culture medium ( Figures 4B and 4C ). Similar results were obtained with iPSCs ( Figures S4B and  S4C ). To determine whether stable ESC lines could be derived from WT and PHF20 KO mice, we found that ESC lines could be readily generated from WT mice, but not from PHF20 KO mice ( Figures S4D and S4E ). WT ESCs expressed AP, Nanog, and Oct4 proteins, whereas cells from PHF20 KO blastocysts did not ( Figure S4E ) and differentiated rapidly into trophectoderm, based on downregulation of Oct4 and upregulation of Cdx2 ( Figure S4F ). These results suggest that PHF20 is required for the generation and maintenance of both ESCs and iPSCs.
To further define the role of PHF20 in iPSC generation, we first knocked down the protein in Tet-O-4F MEFs at different time points and tested its ability to form iPSC colonies. Knockdown of PHF20 in the early stages of reprogramming (i.e., at day 0 or 4) markedly blocked iPSC generation, whereas, in the intermediate or later stages (day 10 or 12), it led to a decreased (but still significant) inhibitory effect on the numbers of iPSC colonies ( Figure 4D ). Using PHF20 KO MEFs ( Figure 4E ), we showed that reprogramming to iPSCs with either 3F or 4F was significantly inhibited in PHF20-deficient MEFs ( Figure 4F) , and the few iPSC colonies that were generated from PHF20-deficient MEFs showed only partially reprogrammed iPSCs ( Figure 4G ), suggesting that PHF20 is required for the efficient generation of fully reprogrammed iPSCs.
Like the results obtained with Jmjd3-deficient MEFs, we found that Jmjd3 knockdown in human fibroblasts enhanced reprogramming, whereas PHF20 knockdown blocked this process ( Figures S4G and S4H ). To clarify how Jmjd3 and PHF20 reciprocally regulate reprogramming, we generated Jmjd3/PHF20 single-or double-KO MEFs and tested their ability to regulate reprogramming. Both Jmjd3-deficient and Jmjd3/PHF20 double-KO MEF cells grew faster than WT and PHF20-deficient cells, but no appreciable difference was observed in the growth between WT and PHF20-deficient cells ( Figure S4I ). As expected, Jmjd3 deletion enhanced reprogramming, but PHF20 ablation inhibited this process (Figure 4H) . Remarkably, Jmjd3 deletion failed to improve reprogramming in Jmjd3 and PHF20 double-KO MEFs ( Figure 4H ), suggesting that the proliferative advantage of Jmjd3-deficient MEFs cannot overcome the failure of reprogramming in PHF20-deficient MEFs. Similar results were obtained when either Ink4a or p21 was knocked down in PHF20-deficient MEFs; that is, loss of each of these regulators increased reprogramming in WT MEFs but failed to rescue defective reprogramming in PHF20-deficient MEFs ( Figure 4I ). Ectopic expression of PHF20, by contrast, restored reprogramming in PHF20-deficient MEFs ( Figure 4J ), suggesting a requirement for expression of this gene in both WT and Jmjd3-deficient MEFs.
To further examine the ability of PHF20 expression to facilitate reprogramming, we generated Tet-O-PHF20 MEFs from rtTA: Tet-O-PHF20 transgenic mice and treated them with Dox, resulting in increased expression of PHF20 compared with Doxtreated rtTA-expressing WT MEFs ( Figure 4K ). More importantly, we observed that Dox-induced expression of PHF20 in these cells led to a marked increase in the efficiency of 4F-mediated reprogramming, compared with Dox-treated rtTA-expressing WT MEFs ( Figure 4K ). Furthermore, overexpression of PHF20 could reverse the Jmjd3-mediated inhibition of reprogramming ( Figure 4L ). The increased reprogramming efficiency in Tet-O-PHF20 MEFs was not due to cellular proliferative activity because there was no appreciable difference in cell growth between WT and Tet-O-PHF20 MEFs, with or without Dox treatment ( Figure S4J ). Instead, Dox-induced expression of PHF20 markedly blocked downregulation of Oct4, Sox2, and Nanog in iPSCs and thus their differentiation after LIF withdrawal ( Figures S4K and S4L) . Nonetheless, PHF20 overexpression could not substitute for any of the 4F ( Figure S4M ). These results indicate an essential requirement for PHF20 in somatic cell reprogramming.
Jmjd3 Interacts with PHF20 and Mediates Its Proteasomal Degradation
To dissect the molecular mechanisms by which Jmjd3 and PHF20 reciprocally control reprogramming, we first showed their localization in the nucleus by immunofluorescent staining and fractionation of ESCs and iPSCs ( Figures S5A and S5B ). Coimmunoprecipitation (co-IP) and western blot analyses of 293T cells transfected with Flag-PHF20 and hemagglutinin (HA)-Jmjd3 revealed that Jmjd3 interacted with PHF20 ( Figure 5A ). Similar results were obtained with WT MEFs, but not with PHF20-deficient MEFs ( Figure 5B ), suggesting that Jmjd3 interacts with PHF20 under physiological conditions. We then performed domain-mapping experiments with Jmjd3-N (1-450 aa), Jmjd3-M (400-1,200 aa), and Jmjd3-C (1,201-1,683 aa), showing that the Jmjd3-N and Jmjd3-C constructs, but not Jmjd3-M, interacted with PHF20 ( Figure 5C ). Similarly, the N-terminal region (1-332 aa containing a DNA-binding domain), but not the C-terminal region, of PHF20 interacted with Jmjd3 ( Figure 5D and Figure S5C ). Further experiments showed that Jmjd3, but not Utx or Uty, interacted with PHF20 ( Figure S5D ), suggesting that Jmjd3 specifically interacts with PHF20 via their functional domains.
What are the functional consequences of the Jmjd3-PHF20 interaction? To address this question, we transfected 293T cells with a fixed amount of Flag-PHF20 together with increasing amounts of HA-Jmjd3 and found that the amounts of PHF20 protein decreased with increasing expression of Jmjd3 protein ( Figure S5E) . Similarly, the amounts of endogenous PHF20 protein were decreased in 293T cells transfected with increasing amounts of Jmjd3 complementary DNA (cDNA) ( Figure 5E ). Furthermore, the amount of endogenous PHF20 protein in Jmjd3-deficient MEFs was much higher than in WT MEFs, whereas ectopic expression of Jmjd3 cDNA in Jmjd3-deficient MEFs reduced the amount of PHF20 protein to a level similar to that in WT MEFs ( Figure 5F ). It therefore appears that Jmjd3 negatively regulates PHF20 protein by targeting it for degradation.
Trim26 Is an E3 Ubiquitin Ligase Required for PHF20 Ubiquitination and Degradation To determine how Jmjd3 causes the degradation of PHF20, we first tested whether PHF20 is ubiquitinated in 293T cells transfected with WT ubiquitin or ubiquitin mutants containing only one lysine, at position 48 (K48) or 63 (K63). Immunoprecipitation and immunoblot analyses revealed that PHF20 was strongly ubiquitinated with ubiquitin mutant K48 but had little or no K63-linked ubiquitination. Furthermore, such a K48-linked ubiquitination was observed only when Jmjd3 and PHF20 were coexpressed ( Figure 6A ), suggesting that Jmjd3 specifically targets PHF20 for K48-linked polyubiquitination.
Because Jmjd3 is not an E3 ubiquitin ligase, we reasoned that Jmjd3 might function as an adaptor to recruit an E3 ubiquitin ligase to PHF20 for ubiquitination. To test this prediction, we designed a screen using 293T cells transfected with Jmjd3 expression vector and a lentivirus-based shRNA sublibrary against human E3 ubiquitin ligases, as previously described (Cui et al., 2012) . In an initial screening of about 600 shRNAs, we identified an E3 ubiquitin ligase (Trim26)-specific shRNA that was associated with increased PHF20 protein amounts, relative to results with control shRNA (Figures S6A and  S6B ). To substantiate this finding, we selected two shRNAs for human Trim26 and three for murine Trim26, with 60%-90% knockdown efficiency ( Figures S6C  and S6D ). Knockdown of endogenous Trim26 by shRNAs markedly abrogated Jmjd3-mediated ubiquitination of PHF20 in 293T cells ( Figure 6B ), with similar results obtained when either Jmjd3 or Trim26 was knocked down in PHF20 +/+ MEFs (Figure S6E) . Consistent with these results, we found that knockdown of Trim26 increased reprogramming efficiency in PHF20 WT MEFs, but not in PHF20-deficient MEFs ( Figure 6C ). Furthermore, knockdown of Trim26 reversed Jmjd3-mediated inhibition of reprogramming ( Figure S6F ), whereas overexpression of Trim26 inhibited reprogramming efficiency enhanced by Jmjd3 knockdown ( Figure S6G ).
Because Trim26 and Jmjd3 could act in concert to modulate reprogramming by targeting PHF20 for ubiquitination and degradation, we next determined their expression patterns during reprogramming and found that Trim26 was decreased, whereas Jmjd3 was increased ( Figure 6D ). As expected, PHF20 expression gradually increased, but PHF20 protein in Jmjd3 À/À MEFs was significantly higher than that in WT cells during reprogramming ( Figures 6D and S6H ). Although treatment with the protease inhibitor MG132 blocked protein degradation even when both Trim26 and Jmjd3 were overexpressed (Figure S6I) , it was nonspecific and caused cell death. Thus, we did not observe any iPSC colony formation after MG132 treatment ( Figure S6J ). We then asked whether ectopic expression of Trim26 would promote PHF20 ubiquitination and degradation. Indeed, coexpression of Trim26 and Jmjd3 led to a remarkable increase in K48-linked ubiquitination and degradation of PHF20, compared with Trim26 or Jmjd3 alone ( Figure 6E ). To determine whether Trim26 interacts with Jmjd3 or PHF20, we performed immunoprecipitation experiments using cells that expressed Jmjd3 or PHF20 alone, three double combinations, or Trim26, Jmjd3, and PHF20 together. Although Trim26 interacted with Jmjd3, but not PHF20 ( Figure 6F ), we detected both Jmjd3 and PHF20 in the anti-Flag-Trim26 immunoprecipitates of the cells that expressed Jmjd3, PHF20, and Trim26 ( Figure 6F ), suggesting that Jmjd3 is an adaptor protein that recruits Trim26 to PHF20. To determine which domain of Jmjd3 is responsible for recruiting Trim26 to PHF20, we transfected 293T cells with Jmjd3-N, Jmjd3-M, or Jmjd3-C, together with Trim26.
Immunoprecipitation and western blot experiments revealed that the N terminus of Jmjd3 (Jmjd3-N), but not Jmjd3-M and Jmjd3-C, was capable of binding to Trim26 ( Figure 6G ). To identify the domain of Jmjd3 that is required for Trim26-mediated ubiquitination of PHF20, we transfected 293T cells with Flag-PHF20, together with HA-tagged Jmjd3-N, Jmjd3-M, Jmjd3-C, Jmjd3-DJmjC, Jmjd3-H1390A, or full-length Jmjd3. After immunoprecipitation with anti-Flag, we assessed K48-linked ubiquitination of PHF20, observing that none of the Jmjd3-N, Jmjd3-M, and Jmjd3-C constructs were sufficient to cause PHF20 ubiquitination ( Figure 6H ). By contrast, like full-length Jmjd3, Jmjd3-DJmjC and Jmjd3-H1390A were able to mediate PHF20 ubiquitination ( Figure 6H ), which is consistent with results showing that Jmjd3-DJmjC and Jmjd3-H1390A could still inhibit iPSC reprogramming in Jmjd3-deficient MEFs ( Figure 3F ). These results suggest that the N terminus of Jmjd3 (Jmjd3-N) can interact with Trim26 but is not sufficient to cause PHF20 ubiquitination. Either WT Jmjd3 or mutant Jmjd3 containing the first 1,200 aa or a point mutation (Jmjd3-DJmjC or Jmjd3-H1390A) is necessary and sufficient to target PHF20 for ubiquitination by recruiting the E3 ligase Trim26.
PHF20 Is Required for Endogenous Oct4 Expression and Interacts with Wdr5 during Reprogramming
Because PHF20 is essential for reprogramming in both WT and Jmjd3-deficient MEFs, we reasoned that it might be required for the reactivation of endogenous key genes such as Oct4 and other markers of ESCs. To test this prediction, we examined the effects of PHF20 loss on the activation of 11 ESC markers during Tet-O-4F reprogramming, using WT and PHF20
À/À
MEFs in the presence of Dox for the first 10 days (followed by withdrawal). Real-time PCR analysis on day 14 revealed that expression of Oct4, Sox2, Nanog, Dnmt3l, Esg1, Eras, Rex1, and Cripto could not be activated or substantially reduced in PHF20-deficient MEFs but were highly activated in WT MEFs. By contrast, Stat3, Grb2, and b-catenin were activated normally in both WT and PHF20-deficient cells ( Figure 7A ). Notably, Sox2 and Nanog could be reactivated when Dox was retained during reprogramming ( Figure S7A ). Overexpression of Oct4 or even 4F could not rescue the incompletely reprogrammed phenotype of PHF20-deficient MEFs after reprogramming ( Figure S7B ), suggesting that PHF20 is an upstream factor that controls many key reprogramming and pluripotency factors.
Because reactivation of endogenous Oct4 is essential for the generation of completely reprogrammed iPSCs (Ang et al., 2011) , we next determined whether PHF20 could directly bind to the Oct4 promoter in vivo. Chromatin immunoprecipitation (ChIP)-PCR assay revealed that PHF20 was strongly bound to this promoter in WT ESCs and iPSCs, but not in PHF20-deficient (differentiated) ESCs and (incompletely reprogrammed) iPSCs ( Figures 7B and 7C ). PHF20 was unable to bind to the promoter regions of Cripto, Dnmt3l, Esg1, Eras, Nanog, Rex1, or Sox2 ( Figure S7C) . Furthermore, the binding of PHF20 to the Oct4 promoter increased gradually over the course of reprogramming ( Figure 7D ). To further determine whether overexpression of PHF20 could promote expression of endogenous Oct4, we treated both WT and Tet-O-PHF20 MEFs expressing rtTA with Dox during 4F-mediated reprogramming. The expression level of Oct4 was markedly increased in Dox-treated Tet-O-PHF20 MEFs, compared with Dox-treated rtTA-expressing WT MEFs ( Figure 7E ), suggesting that PHF20 promotes endogenous Oct4 gene expression during reprogramming.
Because the DNA methylation status of the Oct4 promoter serves as an important marker of fully reprogrammed iPSCs (Stadtfeld and Hochedlinger, 2010) , we undertook bisulfate sequencing analysis of ESCs and iPSCs generated from WT MEFs, which showed robust DNA demethylation in the Oct4 promoter regions. By contrast, incompletely reprogrammed iPSC colonies from PHF20-deficient MEFs retained their DNA methylation pattern ( Figure 7F ). More importantly, we showed that ectopic expression of PHF20 could rescue the incompletely reprogrammed state of PHF20-deficient iPSCs and the methylation status of the Oct4 promoter, similar to results for WT iPSCs ( Figure 7F ).
PHF20 is a component of mixed-lineage leukemia (MLL) H3K34 methyltransferase complexes with the core components MLL, ASH2L, WDR5, and RBBP5, as well as a component of the H4K16 acetyltransferase MOF (males absent on the first, also called MYST1 or KAT8) complex (Cai et al., 2010; Dou et al., 2005; Wysocka et al., 2005) . Importantly, Wdr5 is also a key component shared by MLL H3K4 methyltransferase and the H4K16 acetyltransferase MOF (Cai et al., 2010; Dou et al., 2005; Wysocka et al., 2005) . However, it is not known whether PHF20 interacts with Wdr5 or other components of these two complexes. Because PHF20 is upregulated and binds to the Oct4 promoter during reprogramming, we predicted that PHF20 might interact with Wdr5 to promote endogenous Oct4 expression during reprogramming. To test this possibility, we transfected 293T cells with PHF20, together with Wdr5, MLL3, Dpy-30, Ash2l, or RbBP5, all core components of the H3K4 methyltransferase complex (Trievel and Shilatifard, 2009 ). PHF20 interacted with Wdr5, but not with other proteins tested ( Figures 7G and S7D) . Endogenous interactions between PHF20 and Wdr5 or RbBP5 (but not Ash2L) were observed in iPSCs ( Figure 7H ). ChIP-seq analysis of ESCs and iPSCs confirmed that both PHF20 and Wdr5 were bound to the Oct4 promoter ( Figure S7E ). Among 6,209 genes bound by PHF20 and 7,774 genes bound by Wdr5, $2,348 genes were co-occupied by PHF20 and Wdr5 in ESCs ( Figure S7F and Table S3 ). In determining the PHF20 and Wdr5 binding distribution relative to gene structure (i.e., 5 0 distal, 5 0 proximal, 5 0 UTR, coding, intron, 3 0 UTR, 3 0 proximal, and 3 0 distal regions), we found that the majority of PHF20 and Wdr5 binding sites were mapped to the gene body (coding and intron regions) and 5 0 proximal region in ESCs ( Figure S7G ). The distribution of PHF20 was more pronounced toward the 5 0 end of genes with 9.7% of peaks at the 5 0 proximal region, compared to 2.8% at the 3 0 proximal region ( Figure S7G) . Consistent with this, we found that both PHF20 and Wdr5 binding peaks centered on the transcriptional start site (TSS) within a 7 kb region (from À2 to +5 kb) (Figure S7H) . To determine the functional relevance of target genes bound by PHF20 or by PHF20 and Wdr5, we performed gene ontology (GO) analysis and found that binding targets were enriched for genes involved in cell and organ developmental processes, embryonic development, and cell differentiation ( Figure S7I ). 
(legend continued on next page)
To determine whether PHF20 interacts with MOF, we performed co-IP with anti-PHF20 and found that PHF20 interacted with endogenous MOF in iPSCs ( Figure 7H ), which is consistent with the results of a recent report showing that H3K4 methylation is closely associated with H4K16 acetylation . Thus, PHF20 interacts with Wdr5 and MOF to bring the H3K4 methyltransferase and H4K16 acetyltransferase MOF complexes together. To understand how the loss of PHF20 results in failure to reactivate endogenous Oct4 expression, we tested the possibility that PHF20 might affect the ability of Wdr5, RbBP5, and MOF to bind to the Oct4 promoter region. In ChIP-qPCR experiments with WT and PHF20-deficient cells, Wdr5 failed to bind to the Oct4 promoter in PHF20-deficient cells but bound strongly to the Oct4 promoter in WT cells ( Figure 7I) . Similarly, the ability of RbBP5 and MOF to bind to the Oct4 promoter was markedly reduced in PHF20-deficient cells. Consistent with these results, ChIP-qPCR experiments revealed a sharp reduction in H3K4 trimethylation at the Oct4 promoter, whereas H4K16 acetylation was also affected but to a lesser extent ( Figure 7J ). Taken together, these results suggest that binding of PHF20 to the Oct4 promoter may be required for recruiting the H3K4 methyltransferase complex and perhaps the H4K16 acetyltransferase complex to bind to the same promoter through the interaction with Wdr5 and MOF, leading to reactivation of endogenous Oct4 expression during reprogramming.
DISCUSSION
Using a shRNA knockdown screen in Tet-O-4F MEFs, we identified a number of histone-modifying proteins that are required for the reprogramming of somatic cells to iPSCs, but only one, Jmjd3, functions as a negative regulator of this process. Given the sequential multistep nature of iPSC generation (Plath and Lowry, 2011) , it is not surprising that negative regulators of reprogramming exist. Indeed, DOT1L was recently shown to negatively control Nanog and LIN28 expression, posing an unexpected barrier to efficient reprogramming (Onder et al., 2012) . Until the full spectrum of such regulators is delineated and their mechanisms of action deciphered, it will be difficult to revise current approaches to iPSC generation with any degree of confidence.
Jmjd3 plays a critical role in the upregulation of Ink4a/Arf by modulating the levels of H3K27 trimethylation in the promoter (Agger et al., 2009; Barradas et al., 2009) . These effects on the expression of Ink4a/Arf and p21, in turn, induce senescence and inhibit reprogramming (Hong et al., 2009; Kawamura et al., 2009; Li et al., 2009; Marió n et al., 2009; Utikal et al., 2009) , which is consistent with our demonstration that Jmjd3 ablation reduces cell senescence and promotes reprogramming of Jmjd3-deficient MEFs. However, we provide several lines of evidence indicating that Jmjd3 can regulate reprogramming through a previously unrecognized, histone demethylase activity-independent pathway. First, the combined knockdown of Jmjd3 with Ink4a or p21 resulted in significantly more iPSC colonies than did knockdown of any single gene alone. Second, although ectopic expression of full-length Jmjd3 in Jmjd3-deficient MEFs restored Ink4a/Arf expression and strongly inhibited the efficiency of reprogramming, the Jmjd3 mutants Jmjd3-DJmjC and Jmjd3-H1390A, defined by their lack of H3K27me3 demethylase activity and inability to upregulate Ink4a/Arf expression, could still inhibit reprogramming in Jmjd3-deficient MEFs. We therefore propose that Jmjd3 exploits both demethylase activity-dependent and -independent mechanisms to regulate somatic cell reprogramming, with the latter having a predominant role.
An extensive search for target molecules that might be involved in a Jmjd3-mediated but demethylase activity-independent pathway led to the identification of PHF20. We provide evidence of a critical role for PHF20 expression in the maintenance of the pluripotent state. PHF20 was first identified as an antibody-reactive protein that is highly expressed in several types of cancer (Fischer et al., 2001; Wang et al., 2002) . PHF20 has since been identified as a histone code reader that specifically recognizes the dimethylation of H3K4, H3K9, H4K20, and H4K79 (Adams-Cioaba et al., 2012; Kim et al., 2006) . Recent studies show that it also regulates p53 at both the transcriptional and posttranscriptional levels in response to DNA damage (Li et al., 2013; Park et al., 2012) . Mice with PHF20 ablation die shortly after birth (Badeaux et al., 2012) . Consistently, we failed to generate ESC lines from PHF20 KO mice. PHF20 deficiency almost completely inhibits reprogramming of PHF20-deficient MEFs, suggesting an absolute . See also Figure S7 and Table S3 .
requirement for this factor in iPSC reprogramming and generation of ESCs. Jmjd3 has been shown to play an important role in T cell lineage commitment by interacting with T-bet and Brg1 in a demethylase activity-independent manner (Miller et al., 2010) . Here, we show that Jmjd3 interacts with PHF20, targeting it for ubiquitination and proteasomal degradation. Although both the N-and C-terminal regions of Jmjd3 protein can bind to the N terminus of PHF20, Jmjd3 itself cannot ubiquitinate PHF20. Instead, it recruits an E3 ligase, Trim26, to PHF20 for K48-linked polyubiquitination. Indeed, knockdown of Trim26 abolishes PHF20 ubiquitination and degradation, thus enhancing iPSC reprogramming. Further experiments demonstrated that, like full-length Jmjd3, certain Jmjd3 mutants (Jmjd3-DJmjC and Jmjd3-H1390A), but not Jmjd3-N, Jmjd3-M, or Jmjd3-C, target PHF20 for ubiquitination. These results emphasize the importance of Jmjd3-Trim26-mediated ubiquitination in the negative regulation of reprogramming.
Fully reprogrammed iPSCs are accompanied by changes in distinct DNA methylation patterns associated with reactivation of endogenous Oct4 and several other ESC marker genes (Plath and Lowry, 2011; Stadtfeld and Hochedlinger, 2010) . How, then, does PHF20 deficiency lead to failure to reactivate these endogenous marker genes, thus imposing a major barrier to successful reprogramming? A recent study shows that exogenous Oct4, together with other key reprogramming factors, first induces Wdr5 expression in MEFs, which, in turn, promotes formation of a Wdr5-Oct4 complex that binds to the Oct4 promoter, leading to reactivation of endogenous Oct4 expression (Ang et al., 2011) . To directly link PHF20 to Oct4 expression, we show that PHF20 not only binds to the Oct4 promoter region but also specifically interacts with Wdr5 and MOF. A recent study shows that MOF is required for ESC self-renewal and function and regulates Nanog expression . Deletion of PHF20 reduces the ability of Wdr5 and MOF to bind to the Oct4 promoter, suggesting a critical requirement for this protein in reactivation of endogenous Oct4 expression and, hence, for successful generation of fully reprogrammed iPSCs. Consistent with this notion, our results further demonstrated that PHF20 deficiency results in failure to reactivate expression of many endogenous ESC marker genes during reprogramming, suggesting that PHF20 affects expression of many key ESC genes directly or indirectly. ChIP-qPCR and ChIP-seq analyses show that PHF20 and Wdr5 bind to the Oct4 promoter, but not to the promoter regions of Sox2, Nanog, Dnmt3l, Esg1, Eras, Rex1, and Cripto. In addition, ChIP-seq analysis revealed that both PHF20 and Wdr5 bind to several key epigenetic factor genes, including Baf155, Brg1, and Sall4. Hence, these findings explain why the incompletely reprogrammed phenotype of PHF20-deficient MEFs cannot be rescued by overexpression of Oct4 or 4F (OSKM) and further suggest that PHF20 functions as an upstream regulator that controls Oct4 and many other critical ESC marker genes, thus providing a mechanistic link between Jmjd3-mediated PHF20 degradation and deficient reprogramming.
On the basis of these findings, we propose a working model to explain how the Jmjd3-PHF20 axis regulates iPSC reprogramming. Increased expression of Jmjd3 due to 4F-mediated reprogramming in WT MEFs initiates at least two distinct pathways ( Figure 7K ): (1) Jmjd3 upregulates Ink4a/Arf and p21 by modulating H3K4 and H3K27 methylation through its H3K27me2/3 demethylase activity. Increased amounts of Ink4a, Arf, and p21 induce cell senescence or apoptosis and reduce cell proliferation, thus decreasing the efficiency and kinetics of reprogramming. (2) Jmjd3 protein also targets PHF20 for ubiquitination and degradation by recruiting an E3 ligase, Trim26, in an H3K27 demethylase activity-independent manner. The resultant decrease in PHF20 protein leads to the loss or negligible expression of endogenous Oct4, thereby greatly reducing reprogramming efficiency. We conclude that the demethylase activity-dependent and -independent pathways used by Jmjd3 act in concert to potently restrain the kinetics and efficiency of reprogramming. The observations that Jmjd3 loss reduces cell senescence and apoptosis and increases cell proliferation and that increased amounts of PHF20 lead to reactivation of endogenous Oct4 expression suggest means to enhance the outcome of somatic cell reprogramming overall.
EXPERIMENTAL PROCEDURES Mice
Tet-O-Sox2 and -Klf4 transgenic mice were generated and crossed with Rosa-rtTA, Tet-O-Oct4 (from the Jackson Laboratories), and Tet-O-Myc transgenic mice. Tet-O-4F MEFs that express rtTA and Tet-O-Oct4, Sox2, Klf4, and Myc were established and used for reprogramming. Tet-O-PHF20 mice were generated as Tet-O-Sox2 and -Klf4 transgenic mice. Jmjd3 was deleted at exons 15-21 using a Cre-LoxP system. Jmjd3 was globally deleted by crossing Jmjd3 f/f mice with Hprt-Cre mice (Jackson Laboratories).
Generation of iPSCs from MEFs and Tet-O-4F MEFs
Mouse iPSCs were generated from MEFs, as previously described (Takahashi et al., 2007a) , with some minor modifications. Tet-O-4F MEFs were used to generate iPSCs by treating MEFs with Dox in mESC medium. The efficiency of iPSC formation was calculated based on the number of AP + iPSC colonies and the initial cell number of seeded MEFs. Human iPSCs were generated as previously described (Park et al., 2008) . Lentiviral particles were generated and concentrated as previously described (Peng et al., 2005) .
Screening for Epigenetic Factors that Modulate Reprogramming Efficiency
Tet-O-4F transgenic MEF cells (M2-11) were transduced with lentivirus-based shRNAs specific for 15 epigenetic factors and then reseeded on irradiated feeder cells at the desired density. The next day, mESC medium containing 2 mg/ml Dox was added and replenished every day. The colonies were stained for AP activity on days 12-14.
Co-IP, ChIP-PCR, and ChIP-Seq Analysis
The cells were lysed in RIPA buffer and analyzed as previously described (Cui et al., 2010) . ChIP assay was performed with Imprint Ultra Chromatin Immunoprecipitation kit (Sigma). ChIP-seq libraries were prepared, sequenced, and analyzed. See Extended Experimental Procedures for details.
ACCESSION NUMBERS
The ChIP-seq data are available at the Gene Expression Omnibus under the accession number GSE43247. 
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